Last reviewed · How we verify
Salonpas (METHYL SALICYLATE)
Methyl Salicylate, marketed as Salonpas by Hisamitsu Pharmaceutical Co., is a topical analgesic primarily indicated for arthritic pain relief and holds a significant market presence. Its key strength lies in the mechanism of action, where methyl salicylate is absorbed through the skin to block pain signals to the brain, providing targeted relief. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic products.
At a glance
| Generic name | METHYL SALICYLATE |
|---|---|
| Sponsor | Hisamitsu Pharm Co |
| Drug class | methyl salicylate |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
- Arthritic Pain
- Backache
- Sprains and Strains
Common side effects
Drug interactions
- phenprocoumon
- warfarin
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
- Impact of Cooling Mats on Vasomotor Symptoms in Patients Receiving Endocrine Therapy (NA)
- Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention (PHASE2)
- The Antiplaque and Antigingivitis Effect of Pure Green Tea Mouth Wash Compared to Placebo and Essential Oils Mouth Washes (NA)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2,PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Study of Gum Tissue Proteins in Smokers vs. Non-smokers After Cleaning (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salonpas CI brief — competitive landscape report
- Salonpas updates RSS · CI watch RSS
- Hisamitsu Pharm Co portfolio CI